Analyzing VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI)

VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for VectivBio and Senti Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0	0	0	0	0.00
Senti Biosciences	0	0	1	0	3.00

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 151.89%. Given Senti Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than VectivBio.

Volatility & Risk

VectivBio has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500.

Profitability

This table compares VectivBio and Senti Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Senti Biosciences	N/A	-154.84%	-77.42%

Earnings and Valuation

This table compares VectivBio and Senti Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	$27.34 million	20.97	-$93.74 million	N/A	N/A
Senti Biosciences	$2.56 million	7.12	-$71.06 million	($15.56)	-0.26

Senti Biosciences has lower revenue, but higher earnings than VectivBio.

Institutional and Insider Ownership

25.7% of Senti Biosciences shares are held by institutional investors. 9.7% of VectivBio shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Senti Biosciences beats VectivBio on 7 of the 11 factors compared between the two stocks.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.